RxDoctor Payments Data

Tracy Moll, DO

Neurology · Rockingham, VANPI 1427430396

Payments from drug & device makers

$2,362in general payments, 2019–2025

Across 26 payments — averaging $90.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Beckman Coulter, Inc.$837
  • Biogen$174
  • AstraZeneca$152
  • Sanofi$139
  • AbbVie$137
  • Biohaven Pharmaceutical Holding Company Ltd.$125
  • plus $798 from 12 others

What the payments were for

  • Speaking & faculty fees$60025%
  • Travel & lodging$1306%
  • Food & beverage$1,54765%
  • Education$864%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,362 in reported general payments places this provider in the 55th percentile of 474 neurology providers in Virginia.

See all neurology providers in Virginia

Medicare billing

Part B allowed, 2024
$144,402
Medicare patients
490
Services billed
2,675

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VumerityDiroximel Fumarate14$118,449
IngrezzaValbenazine Tosylate13$107,075
Nurtec OdtRimegepant Sulfate35$48,392
BriviactBrivaracetam12$29,804
Aimovig AutoinjectorErenumab-Aooe25$23,343
Emgality PenGalcanezumab-Gnlm19$14,861
XcopriCenobamate11$14,685
RivastigmineRivastigmine Tartrate199$13,263
UbrelvyUbrogepant11$10,951
Ajovy AutoinjectorFremanezumab-Vfrm13$9,361
EliquisApixaban17$9,304
Levetiracetam280$7,521
Carbidopa-LevodopaCarbidopa/Levodopa216$7,456
Lamotrigine OdtLamotrigine17$4,943
Primidone115$4,752

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenVumerity$174$118,44914 claims
SK Life Science, Inc.Xcopri$80$14,68511 claims
AbbVieUbrelvy$137$10,95111 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$100$1,37816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 474 neurology providers in Virginia.

Other neurology in Rockingham

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →